Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Medicinova, inc. save search
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
Published: 2024-03-26 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 2.21%
H: 5.76%
C: 5.76%
mn-166 patent japan macular treatment
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
Published: 2024-01-17 (Crawled : 11:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 0.0%
H: 0.66%
C: -1.32%
mn-166 patent macular treatment grant china
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
Published: 2023-12-06 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 0.0%
H: 4.17%
C: 4.17%
mn-166 europe patent treatment grant
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
Published: 2023-10-27 (Crawled : 05:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: -1.54%
treatment phenylketonuria therapy
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
Published: 2023-10-10 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 1.15%
H: 1.15%
C: -1.14%
mn-166 patent riluzole sclerosis treatment canada
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
Published: 2023-08-16 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.63%
mn-166 europe patent macular treatment grant
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
Published: 2023-08-15 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 6.93%
H: 2.83%
C: 0.0%
mn-001 europe patent sclerosis treatment
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
Published: 2023-08-14 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: -3.75%
mn-001 europe patent treatment grant nash
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
Published: 2023-04-30 (Crawled : 00:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 1.42%
H: 2.8%
C: -2.34%
mn-001 patent treatment canada nash
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
Published: 2023-01-12 (Crawled : 00:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.8%
mn-166 treatment trial glioblastoma
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
Published: 2023-01-11 (Crawled : 04:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 4.9%
H: 0.39%
C: -1.17%
mn-001 treatment patent canada sclerosis
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil
Published: 2023-01-10 (Crawled : 04:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 0.41%
H: 2.04%
C: 0.0%
mn-001 treatment patent brazil hypercholesterolemia
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
Published: 2022-09-14 (Crawled : 00:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: -0.46%
H: 4.65%
C: 2.33%
mn-166 treatment patent glioblastoma
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
Published: 2022-09-13 (Crawled : 00:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 2.82%
H: 2.74%
C: -1.37%
mn-001 treatment patent canada hypercholesterolemia
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
Published: 2022-08-16 (Crawled : 11:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: -1.21%
H: 1.22%
C: -0.41%
mn-166 treatment covid trial agreement
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
Published: 2022-07-27 (Crawled : 11:00) - globenewswire.com
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 2.16%
H: 0.34%
C: -2.52%
mn-001 treatment fibrosis patent
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea
Published: 2022-03-17 (Crawled : 12:00) - biospace.com/
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 1.05%
H: 2.09%
C: 1.46%
mn-001 treatment patent nash
MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal
Published: 2022-02-28 (Crawled : 12:30) - biospace.com/
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 1.66%
H: 2.04%
C: -2.45%
mn-166 treatment spine potential therapy
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe
Published: 2022-01-27 (Crawled : 12:30) - biospace.com/
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: -6.0%
mn-166 alcohol use disorder treatment europe order patent grant
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS
Published: 2021-12-13 (Crawled : 12:30) - biospace.com/
MNOV | $1.34 -3.6% -3.73% 17K
|
Health Technology
|
| O: 2.22%
H: 0.0%
C: 0.0%
mn-166 treatment patent als parkinson
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.